Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone
FDA may have to exit its drug review comfort zone and accept more trials outside the classic double-blind, placebo-controlled realm to promote more orphan drug development, industry and advocacy organizations told the agency
You may also be interested in...
Attorneys' proposal aims to better connect dispersed rare disease expertise within FDA's drug, biologic, and device centers through more leadership, new advisory committee.
Reviewer expertise may be better leveraged in more focused roles, but basic tenets of rare disease program should not fundamentally change as part of proposed Office of New Drugs reorganization.
CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.